• 1. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Phenylpiperazines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazinanes Piperazines Phenylpiperazines

Research Brief on tert-Butyl 4-(3-amino-5-morpholinophenyl)piperazine-1-carboxylate (CAS: 1051899-49-0)

In recent years, the compound tert-Butyl 4-(3-amino-5-morpholinophenyl)piperazine-1-carboxylate (CAS: 1051899-49-0) has garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its piperazine and morpholine moieties, has shown promising potential as a key intermediate in the synthesis of bioactive compounds targeting various diseases, including cancer and neurological disorders. The unique structural features of this compound make it a valuable scaffold for drug discovery and development.

Recent studies have focused on the synthesis and optimization of tert-Butyl 4-(3-amino-5-morpholinophenyl)piperazine-1-carboxylate to enhance its pharmacological properties. Researchers have employed advanced synthetic techniques, such as multi-step organic reactions and catalytic methods, to achieve high yields and purity. The compound's ability to interact with specific biological targets, such as kinases and GPCRs, has been explored in vitro and in silico, revealing its potential as a modulator of critical signaling pathways.

One of the most notable applications of this compound is its role in the development of kinase inhibitors. Kinases play a pivotal role in cell proliferation and survival, and their dysregulation is often associated with cancer. Preliminary studies have demonstrated that derivatives of tert-Butyl 4-(3-amino-5-morpholinophenyl)piperazine-1-carboxylate exhibit inhibitory activity against certain oncogenic kinases, suggesting their potential as anticancer agents. Further investigations are underway to evaluate their efficacy and safety in preclinical models.

In addition to its anticancer potential, this compound has also been investigated for its neuroprotective effects. The morpholine and piperazine groups are known to enhance blood-brain barrier permeability, making the compound a candidate for treating neurological disorders such as Alzheimer's and Parkinson's diseases. Recent in vivo studies have shown that the compound can modulate neurotransmitter systems and reduce oxidative stress, highlighting its multifaceted therapeutic potential.

Despite these promising findings, challenges remain in the development of tert-Butyl 4-(3-amino-5-morpholinophenyl)piperazine-1-carboxylate-based therapeutics. Issues such as metabolic stability, bioavailability, and potential off-target effects need to be addressed through further structural optimization and pharmacokinetic studies. Collaborative efforts between academic institutions and pharmaceutical companies are essential to accelerate the translation of these discoveries into clinical applications.

In conclusion, tert-Butyl 4-(3-amino-5-morpholinophenyl)piperazine-1-carboxylate (CAS: 1051899-49-0) represents a versatile and promising scaffold in medicinal chemistry. Its applications in oncology and neurology, coupled with ongoing research efforts, underscore its potential to contribute to the development of next-generation therapeutics. Future studies should focus on elucidating its mechanism of action and optimizing its drug-like properties to fully realize its therapeutic benefits.

• 77278-63-8(tert-Butyl 4-Phenylpiperazine-1-carboxylate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)